The stock has a 36-month beta value of 1.19. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNSP is 10.14M, and at present, short sellers hold a 0.23% of that float. On May 07, 2024, the average trading volume of CNSP was 306.61K shares.
CNSP) stock’s latest price update
Cns Pharmaceuticals Inc (NASDAQ: CNSP)’s stock price has gone decline by -8.64 in comparison to its previous close of 0.22, however, the company has experienced a -6.05% decrease in its stock price over the last five trading days. Accesswire reported 2024-04-23 that Presentation on Monday, April 29th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM (GMT+1) in London, England. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
CNSP’s Market Performance
Cns Pharmaceuticals Inc (CNSP) has seen a -6.05% fall in stock performance for the week, with a -21.89% decline in the past month and a -22.81% plunge in the past quarter. The volatility ratio for the week is 8.81%, and the volatility levels for the past 30 days are at 10.77% for CNSP. The simple moving average for the past 20 days is -7.22% for CNSP’s stock, with a -82.65% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -32.00% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.22% of loss for the given period.
Volatility was left at 10.77%, however, over the last 30 days, the volatility rate increased by 8.81%, as shares sank -9.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.63% lower at present.
During the last 5 trading sessions, CNSP fell by -6.05%, which changed the moving average for the period of 200-days by -90.56% in comparison to the 20-day moving average, which settled at $0.2166. In addition, Cns Pharmaceuticals Inc saw -84.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNSP starting from Climaco John M, who purchase 166,666 shares at the price of $0.30 back on Feb 01 ’24. After this action, Climaco John M now owns 215,676 shares of Cns Pharmaceuticals Inc, valued at $50,000 using the latest closing price.
Downs Christopher, the Chief Financial Officer of Cns Pharmaceuticals Inc, purchase 66,666 shares at $0.30 during a trade that took place back on Feb 01 ’24, which means that Downs Christopher is holding 103,438 shares at $20,000 based on the most recent closing price.
Stock Fundamentals for CNSP
The total capital return value is set at 4.26. Equity return is now at value -1018.78, with -255.54 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -47.01. The debt to equity ratio resting at -0.07. The interest coverage ratio of the stock is -1366.54.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
To sum up, Cns Pharmaceuticals Inc (CNSP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
